United therapeutics corporation UTHR.US Overview Analysis
)UTHR AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has received the highest rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
UTHR Current Performance
0.26%
United therapeutics corporation
3.56%
Avg of Sector
1.47%
S&P500
Top 10 High Relevance to UTHR
- TEM Tempus ai incValue -Trend 3Swing Trading 4Whale Interest 3Dividend 1See more
UTHR Profile
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind's Afrezza (insulin human) Inhalation Powder product.